tradingkey.logo

Clearpoint Neuro Inc

CLPT
15.810USD
-2.420-13.27%
Close 11/07, 16:00ETQuotes delayed by 15 min
449.45MMarket Cap
LossP/E TTM

Clearpoint Neuro Inc

15.810
-2.420-13.27%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Clearpoint Neuro Inc

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Clearpoint Neuro Inc's Score

Industry at a Glance

Industry Ranking
102 / 209
Overall Ranking
225 / 4614
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 2 analysts
Buy
Current Rating
29.000
Target Price
+83.43%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Clearpoint Neuro Inc Highlights

StrengthsRisks
ClearPoint Neuro, Inc. is a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. The Company’s flagship product is the ClearPoint Neuro Navigation System. Its initial product offering, the ClearPoint system, is an integrated system comprised of capital equipment and disposable products, designed to allow minimally invasive procedures in the brain to be performed in a magnetic resonance imaging (MRI) suite. The ClearPoint Array Neuro Navigation System and its principal disposable component is designed to be deployed in an operating room setting while also being usable in an MRI suite. It is engaged with healthcare and research centers in North America, Europe, Asia, and South America. It also provides solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 52.74% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 31.39M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 31.39M.
Undervalued
The company’s latest PE is -19.12, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 11.08M shares, increasing 2.83% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 13.85K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.61.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 7.77, which is higher than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 8.86M, representing a year-over-year increase of 9.10%, while its net profit experienced a year-over-year increase of 18.44%.

Score

Industry at a Glance

Previous score
7.77
Change
0

Financials

8.01

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

7.06

Operational Efficiency

8.68

Growth Potential

7.84

Shareholder Returns

7.28

Clearpoint Neuro Inc's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 7.11, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -19.12, which is -73.76% below the recent high of -5.02 and -93.40% above the recent low of -36.98.

Score

Industry at a Glance

Previous score
7.11
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 102/209
No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Clearpoint Neuro Inc is 29.00, with a high of 30.00 and a low of 28.00.

Score

Industry at a Glance

Previous score
8.00
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts
Buy
Current Rating
29.000
Target Price
+83.43%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

89
Total
4
Median
7
Average
Company name
Ratings
Analysts
Clearpoint Neuro Inc
CLPT
2
Boston Scientific Corp
BSX
37
Intuitive Surgical Inc
ISRG
35
Edwards Lifesciences Corp
EW
35
Veeva Systems Inc
VEEV
34
Thermo Fisher Scientific Inc
TMO
28
1
2
3
...
18

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 6.79, which is lower than the Healthcare Equipment & Supplies industry's average of 6.88. Sideways: Currently, the stock price is trading between the resistance level at 24.37 and the support level at 10.98, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
7.03
Change
-0.24

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-2.826
Neutral
RSI(14)
34.030
Neutral
STOCH(KDJ)(9,3,3)
13.969
Oversold
ATR(14)
2.451
High Vlolatility
CCI(14)
-125.506
Sell
Williams %R
91.242
Oversold
TRIX(12,20)
-0.381
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(4)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MA5
17.508
Sell
MA10
21.099
Sell
MA20
23.269
Sell
MA50
19.322
Sell
MA100
15.233
Buy
MA200
14.608
Buy

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.42. The latest institutional shareholding proportion is 38.97%, representing a quarter-over-quarter decrease of 14.09%. The largest institutional shareholder is The Vanguard, holding a total of 1.48M shares, representing 5.19% of shares outstanding, with 14.80% increase in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
1.50M
+307.45%
The Vanguard Group, Inc.
Star Investors
1.48M
+14.89%
Bigger Capital Funds, LP
1.17M
+2.79%
PTC Therapeutics Inc
894.58K
--
Geode Capital Management, L.L.C.
624.80K
+107.32%
District 2 Capital LP
430.17K
+1.84%
Bigger (Michael)
378.69K
--
State Street Investment Management (US)
333.38K
+164.91%
Brown Advisory
330.90K
-0.06%
Lane Generational, LLC
258.43K
+6.77%
1
2

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 4.58. The company's beta value is 1.01. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
3.00
Change
0
Beta vs S&P 500 index
1.06
VaR
+6.69%
240-Day Maximum Drawdown
+47.09%
240-Day Volatility
+94.11%

Return

Best Daily Return
60 days
+58.55%
120 days
+58.55%
5 years
+58.55%
Worst Daily Return
60 days
-18.17%
120 days
-18.17%
5 years
-18.17%
Sharpe Ratio
60 days
+1.40
120 days
+0.82
5 years
+0.25

Risk Assessment

Maximum Drawdown
240 days
+47.09%
3 years
+58.04%
5 years
+84.62%
Return-to-Drawdown Ratio
240 days
+0.90
3 years
+0.57
5 years
-0.08
Skewness
240 days
+3.43
3 years
+2.86
5 years
+2.13

Volatility

Realised Volatility
240 days
+94.11%
5 years
+81.71%
Standardised True Range
240 days
+6.92%
5 years
+5.30%
Downside Risk-Adjusted Return
120 days
+182.49%
240 days
+182.49%
Maximum Daily Upside Volatility
60 days
+166.19%
Maximum Daily Downside Volatility
60 days
+113.61%

Liquidity

Average Turnover Rate
60 days
+1.51%
120 days
+1.22%
5 years
--
Turnover Deviation
20 days
+61.23%
60 days
+84.84%
120 days
+49.86%

Peer Comparison

Healthcare Equipment & Supplies
Clearpoint Neuro Inc
Clearpoint Neuro Inc
CLPT
6.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
Castle Biosciences Inc
CSTL
8.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
TCMD
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
8.54 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AxoGen Inc
AXGN
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI